Jayne Gershkowitz, the chief patient advocate for Amicus Therapeutics, will receive the Dr. Sol J. Barer Award for Vision, Innovation and Leadership at BioNJ’s annual Innovation Celebration.
The dinner, considered the kickoff event of the year for the life sciences industry in New Jersey, always brings an overflow crowd of hundreds of biopharma professionals, academic leaders, Patients, advocates and service providers together to honor the groundbreaking medical innovation coming from the Garden State. Find out more here.
BioNJ CEO Debbie Hart said the event will honor numerous leaders in the industry.
“Because Patients Can’t Wait, we are incredibly proud of our members who are helping patients live longer, better lives,” she said. “At BioNJ’s Annual Dinner Meeting & Innovation Celebration, we’ll come together to honor the remarkable dedication and transformative work of New Jersey’s life sciences community — a beacon of innovation and hope that turns Patients’ dreams into reality around the globe.
With 21 novel FDA approvals in 2024, New Jersey proudly stands at the forefront of progress, setting the standard for excellence across the nation.”
The 2025 Innovator Award Honorees Include:
- Ascendis Pharma for the approval of Yorvipath
- BeiGene for the approval of Tevimbra
- Bristol Myers Squibb for the approval of Cobenfy
- Bracco Diagnostics for the approval of Iomervu
- Citius Pharmaceuticals for the approval of Lymphir
- Eli Lilly for the approvals of Ebglyss and Kisunla
- Idorsia for the approval of Tryvio
- Ipsen for the approval of Iqirvo
- Galderma for the approval of Nemluvio
- GE HealthCare for the approval of Flyrcado
- Geron for the approval of Rytelo
- Gilead for the approval of Livdelzi
- Johnson & Johnson for the approval of Lazcluze
- Merck & Co. for the approvals of Capvaxive and Winrevair
- Novo Nordisk for the approval of Alhemo
- Pfizer for the approvals of Beqvez and Hympavzi
- PTC Therapeutics for the approval of Kebilidi
- Sun Pharma for the approval of Leqselvi
In addition, there will be a presentation of the Heart of BioNJ Awards recognizing extraordinary Patient Advocates; the opportunity to network with the “Who’s Who” of the industry; an inspirational presentation by 16-year-old Patient Advocate and brain cancer survivor Grace Eline; a closing fireside chat with John Crowley, the CEO of the Biotechnology Innovation Organization and Dr. Peter Marks, the director of the Center for Biologics Evaluation and Research, U.S. Food and Drug Administration.
